NOVO-B Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.…
Industry Peers
Drug Manufacturers - GeneralKey Statistics
About Novo Nordisk (CPH: NOVO-B)
›
Novo Nordisk (CPH: NOVO-B) is listed on Nasdaq Copenhagen, where its shares trade in DKK. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector, and reports about 68,794 employees.
The shares were at 265.15 DKK on 19 November 2026, down 21.3% over 52 weeks. Its 52-week range is 224.25 DKK to 409.95 DKK: the price is 35.3% below the high and 18.2% above the low.
At a market capitalisation of 1.17T DKK, it trades at 10.2 times trailing earnings and 11.7 times forward earnings. The median trailing P/E of its 18 largest Drug Manufacturers - General peers is 26.2, a discount of 61% for NOVO-B. It pays a dividend yielding 4.31% (it pays out 46% of its earnings), against a median of 2.42% among the dividend payers in that peer group.
Novo Nordisk reports return on equity of 52.8%, an operating margin of 50.8% and revenue up 5.6% year over year.
Its debt exceeds its cash by 88.13B DKK, a debt-to-equity ratio of 0.67. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 24 analysts cover the stock, with an average rating of Hold; their mean price target of 299.91 DKK is 13.1% above the current price. The next earnings report is expected on 3 February 2027.